{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:33:07Z","timestamp":1791851587039,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ANR","award":["RHU MyPROBE"],"award-info":[{"award-number":["RHU MyPROBE"]}]},{"name":"ANR","award":["ANR-17-RHUS-0008"],"award-info":[{"award-number":["ANR-17-RHUS-0008"]}]},{"DOI":"10.13039\/501100006364","name":"INCa","doi-asserted-by":"crossref","award":["PAIR SEIN14-049 IDF-ANDRE"],"award-info":[{"award-number":["PAIR SEIN14-049 IDF-ANDRE"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s10549-019-05462-y","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T13:29:07Z","timestamp":1571232547000},"page":"387-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies"],"prefix":"10.1007","volume":"179","author":[{"given":"Dimitri","family":"Carene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Tran-Dien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Canon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Richon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Caux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-2968","authenticated-orcid":false,"given":"Stefan","family":"Michiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"5462_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/dju055","journal-title":"J Natl Cancer Inst"},{"key":"5462_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","volume":"9","author":"M Cianfrocca","year":"2004","unstructured":"Cianfrocca M, Goldstein LJ (2004) Prognostic and predictive factors in early-stage breast cancer. Oncologist 9:606\u2013616","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"5462_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0960-9776(08)70002-X","volume":"17","author":"HS Rugo","year":"2008","unstructured":"Rugo HS (2008) The importance of distant metastases in hormone-sensitive breast cancer. Breast 17(Suppl 1):S3\u2013S8","journal-title":"Breast"},{"key":"5462_CR4","first-page":"22","volume":"1","author":"GMC Rosano","year":"2007","unstructured":"Rosano GMC (2007) The importance of distant metastasis and its impact on survival rates on early-stage hormone receptor-positive breast cancer. US Oncol Dis 1:22\u201325","journal-title":"US Oncol Dis"},{"key":"5462_CR5","first-page":"1021","volume":"18","author":"F Mohammadizadeh","year":"2013","unstructured":"Mohammadizadeh F, Hani M, Ranaee M, Bagheri M (2013) Role of cyclin D1 in breast carcinoma. J Res Med Sci 18:1021\u20131025","journal-title":"J Res Med Sci"},{"key":"5462_CR6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ijc.25034","volume":"127","author":"PG Roy","year":"2010","unstructured":"Roy PG, Pratt N, Purdie CA, Baker L, Ashfield A, Quinlan P et al (2010) High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Int J Cancer 127:355\u2013360","journal-title":"Int J Cancer"},{"key":"5462_CR7","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA et al (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70:2085\u20132094","journal-title":"Cancer Res"},{"key":"5462_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1200\/JCO.2017.35.15_suppl.1013","volume":"35","author":"JZ Drago","year":"2017","unstructured":"Drago JZ, Niemierko A, Spring L, Moy B, Juric D, Isakoff SJ et al (2017) FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer. JCO 35:1013","journal-title":"JCO"},{"key":"5462_CR9","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1158\/0008-5472.CAN-11-3095","volume":"72","author":"JA Vendrell","year":"2012","unstructured":"Vendrell JA, Thollet A, Nguyen NT, Ghayad SE, Vinot S, Bi\u00e8che I et al (2012) ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Cancer Res 72:3593\u20133606","journal-title":"Cancer Res"},{"key":"5462_CR10","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1158\/2159-8290.CD-12-0093","volume":"2","author":"LE Littlepage","year":"2012","unstructured":"Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR et al (2012) The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov 2:638\u2013651","journal-title":"Cancer Discov"},{"key":"5462_CR11","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1038\/onc.2010.289","volume":"29","author":"SR Krig","year":"2010","unstructured":"Krig SR, Miller JK, Frietze S, Beckett LA, Neve RM, Farnham PJ et al (2010) ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene 29:5500\u20135510","journal-title":"Oncogene"},{"key":"5462_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3346\/jkms.2008.23.3.414","volume":"23","author":"Y-S Kim","year":"2008","unstructured":"Kim Y-S, Won YS, Park KS, Song BJ, Kim JS, Oh SJ et al (2008) Prognostic significance of HER2 gene amplification according to stage of breast cancer. J Korean Med Sci 23:414\u2013420","journal-title":"J Korean Med Sci"},{"key":"5462_CR13","first-page":"137","volume":"6","author":"A Borg","year":"1991","unstructured":"Borg A, Baldetorp B, Fern\u00f6 M, Killander D, Olsson H, Sigurdsson H (1991) ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137\u2013143","journal-title":"Oncogene"},{"key":"5462_CR14","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/archsurg.135.12.1469","volume":"135","author":"JA Carr","year":"2000","unstructured":"Carr JA, Havstad S, Zarbo RJ, Divine G, Mackowiak P, Velanovich V (2000) The association of HER-2\/neu amplification with breast cancer recurrence. Arch Surg 135:1469\u20131474","journal-title":"Arch Surg"},{"key":"5462_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/1471-2407-6-245","volume":"6","author":"A Letessier","year":"2006","unstructured":"Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V et al (2006) Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 6:245","journal-title":"BMC Cancer"},{"key":"5462_CR16","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/bcr3113","volume":"14","author":"M Cizkova","year":"2012","unstructured":"Cizkova M, Susini A, Vacher S, Cizeron-Clairac G, Andrieu C, Driouch K et al (2012) PIK3CA mutation impact on survival in breast cancer patients and in ER\u03b1, PR and ERBB2-based subgroups. Breast Cancer Res 14:R28","journal-title":"Breast Cancer Res"},{"key":"5462_CR17","doi-asserted-by":"publisher","first-page":"R70","DOI":"10.1186\/bcr3179","volume":"14","author":"L Fern\u00e1ndez-Cuesta","year":"2012","unstructured":"Fern\u00e1ndez-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth K-S, Quinaux E, Buyse M et al (2012) Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline\/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 14:R70","journal-title":"Breast Cancer Res"},{"key":"5462_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/1947601913513950","volume":"4","author":"TT Pham","year":"2013","unstructured":"Pham TT, Angus SP, Johnson GL (2013) MAP3K1: genomic alterations in cancer and function in promoting cell survival or apoptosis. Genes Cancer 4:419\u2013426","journal-title":"Genes Cancer"},{"key":"5462_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Network Cancer Genome Atlas (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61\u201370","journal-title":"Nature"},{"key":"5462_CR20","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1158\/0008-5472.SABCS-09-602","volume":"69","author":"H Roch\u00e9","year":"2009","unstructured":"Roch\u00e9 H, Allouache D, Romieu G, Bourgeois H, Canon J, Serin D et al (2009) Five-year analysis of the FNCLCC-PACS04 trial: FEC100 vs ED75 for the adjuvant treatment of node positive breast cancer. Cancer Res 69:602","journal-title":"Cancer Res"},{"key":"5462_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346\u2013352","journal-title":"Nature"},{"key":"5462_CR22","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/bioinformatics\/btv718","volume":"32","author":"F Commo","year":"2016","unstructured":"Commo F, Guinney J, Fert\u00e9 C, Bot B, Lefebvre C, Soria J-C et al (2016) rCGH: a comprehensive array-based genomic profile platform for precision medicine. Bioinformatics 32:1402\u20131404","journal-title":"Bioinformatics"},{"key":"5462_CR23","doi-asserted-by":"publisher","first-page":"11565","DOI":"10.1158\/0008-5472.CAN-07-2536","volume":"67","author":"J Ad\u00e9la\u00efde","year":"2007","unstructured":"Ad\u00e9la\u00efde J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F et al (2007) Integrated profiling of basal and luminal breast cancers. Cancer Res 67:11565\u201311575","journal-title":"Cancer Res"},{"key":"5462_CR24","unstructured":"Blanche P. TimeROC: time-dependent ROC curve and AUC for censored survival data. https:\/\/cran.r-project.org\/web\/packages\/timeROC\/timeROC.pdf"},{"key":"5462_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1541-7786.MCR-05-0128","volume":"3","author":"V Gelsi-Boyer","year":"2005","unstructured":"Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Roug\u00e9 C et al (2005) Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res 3:655\u2013667","journal-title":"Mol Cancer Res"},{"key":"5462_CR26","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1038\/s41467-018-05914-x","volume":"9","author":"OL Griffith","year":"2018","unstructured":"Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D et al (2018) The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun 9:3476","journal-title":"Nat Commun"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05462-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05462-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05462-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T02:57:46Z","timestamp":1721876266000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05462-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["5462"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05462-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"10 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no relevant conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the PACS04 study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}